On Friday May 23, the independent Data Safety Monitoring Board (DSBM) reviewed the safety data of the 11 participants of our phase 1b study, including 1-year follow up safety data. The board, comprising Prof. Christian Mazel (orthopaedic spine surgeon), Dr. Leon Timmerman (anesthesiologist and pain specialist), and Prof. Theo Stijnen (biostatistician and chair), did not identify any safety concerns and endorsed the initiation of a subsequent randomized trial.

With this encouraging outcome, SentryX has successfully completed the phase 1b study. The results further validate the safety profile of our implantable anesthetic platform and mark an important step forward as we prepare for the next phase of clinical development.

A heartfelt thank you to all participants, investigators, and partners involved in this study. Your dedication, collaboration, and trust have made this milestone possible.